Evidence map›Paper›PMID 40965349›Full record

ArticleCancer medicine2025

EGFR Mutation Detection in Whole Slide Images of Non-Small Cell Lung Cancers Using a Two-Stage Deep Transfer Learning Approach.

Michele Zanoletti, Filippo Ugolini, Laila El Bachiri, Valeria Pasini, Marco Laurino, Francesco De Logu, Eleonora Melissa, Carolina Marchi, Maria Colombino, Daniela Massi and 4 more

Abstract read
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Michele ZanolettiInstitute of Clinical Physiology, National Research Council, Pisa, Italy.ORCID https://orcid.org/0000-0003-0652-3155
Filippo UgoliniSection of Pathological Anatomy, Careggi University Hospital, Florence, Italy.
Laila El BachiriUnit of Pathological Anatomy and Histology, Azienda Ospedaliero Universitaria, Department of Biomedical Sciences, University of Sassari, Sassari, Italy.ORCID https://orcid.org/0009-0004-4590-8650
Valeria PasiniSection of Pathological Anatomy, Department of Health Sciences, University of Florence, Florence, Italy.
Marco LaurinoInstitute of Clinical Physiology, National Research Council, Pisa, Italy.ORCID https://orcid.org/0000-0003-4798-5196
Francesco De LoguSection of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.
Eleonora MelissaInstitute of Clinical Physiology, National Research Council, Pisa, Italy.
Carolina MarchiDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.
Maria ColombinoInstitute of Genetic and Biomedical Research at the National Research Council, Sassari, Italy.
Daniela MassiSection of Pathological Anatomy, Department of Health Sciences, University of Florence, Florence, Italy.
Guido RindiSection of Anatomic Pathology, Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy.ORCID https://orcid.org/0000-0003-2996-4404
Camilla Eva CominDepartment of Experimental and Clinical Medicine Section of Surgery, Histopathology and Molecular Pathology, University of Florence, Florence, Italy.
Giuseppe PalmieriImmuno-Oncology and Targeted Cancer Biotherapies, University of Sassari-Unit of Cancer Genetics, Institute of Genetic and Biomedical Research at the National Research Council, Sassari, Italy.ORCID https://orcid.org/0000-0002-4350-2276
Antonio CossuUnit of Pathological Anatomy and Histology, Azienda Ospedaliero Universitaria, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.ORCID https://orcid.org/0000-0002-2390-2205

Funding

PNRR M4/C2 Research Program of the Innovation Ecosystem, THE-Tuscany Health Ecosystem ECS_00000017Regione Autonoma della Sardegna RASSR07347
6 · The paper itself

Abstract

backgroundLung cancer (LC) is the leading cause of cancer death worldwide. Non-small cell lung cancer is the most frequent and includes adenocarcinoma and squamous cell carcinoma. Currently, LC treatment is based on tumor molecular profiling. LC may display Epidermal Growth Factor Receptor (EGFR) gene mutation. Detecting mutations in the EGFR gene is crucial for the tyrosine kinase inhibitory therapy.

methodsThis study used a computer-based methodology with two Convolutional Neural Networks (CNNs) based on InceptionResNet-V2, applied to Whole Slide Images, to distinguish healthy from cancerous tissue and then EGFR mutated tumor tissue samples. We also integrated an Explainable AI technique (Grad-CAM) to clearly visualize insights into the model's decision-making process. The analysis was conducted on 259 LC cases collected from three different centers (Florence, Rome, and Sassari).

resultsThis methodology achieved an accuracy of 96.17% in distinguishing healthy from cancerous tissue, with specificity of 87.89%, sensitivity of 98.43%, an F1 score of 97.59% and an AUC of 0.99. Additionally, Cohen's Kappa indicated a consistency of 0.7982, and the confusion matrix showed a correct classification rate of 96.2%. For EGFR mutation detection in cancer tissue, slide-level performance after aggregation reached an accuracy of 76.67% with specificity of 80.77%, sensitivity of 73.53%, an F1 score of 78.12%, a consistency of 0.5583 of Cohen's Kappa and an AUC of 0.77. The confusion matrix showed 76.7% as a correct classification rate.

conclusionThe two tested CNNs showed potential for assisting LC diagnosis, especially in distinguishing healthy from tumor tissue. While the direct detection of EGFR mutational status remains challenging, the results suggest that relevant predictive signals can still be extracted from routine H&E slides.

Indexed as

Carcinoma, Non-Small-Cell LungDeep LearningLung NeoplasmsMutationDNA Mutational AnalysisErbB ReceptorsFemaleHumansMaleNeural Networks, ComputerEGFR protein, humanErbB Receptorsadenocarcinomaartificial intelligenceCNNdeep learningdigital pathologyEGFR mutationexplainabilitynon‐small cell lung cancerWSI

Identifiers

PMID40965349
PMCPMC12445122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.